Clinical Data ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPD Pharmaceutical TechnologyPABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD.RespiratoryRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology PABPC4 genetic variants found to be associated with mitochondrial dysfunction driving emphysema in COPD. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosisNext: Bayer gets swift review for Kerendia in type 1 diabetes Related Stories Clinical Data Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test pharminent June 11, 2026 Clinical Data ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data pharminent June 9, 2026 Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes pharminent June 9, 2026
